Public criticisms of pharma patents are “way overstated”, Kathi Vidal tells IAM
The USPTO director shares her thoughts on life sciences IP rights and ongoing collaboration with the FDA
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.